Jan 08, 2020
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
Dec 11, 2019
Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
Sep 25, 2019
Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications
Sep 09, 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Aug 15, 2019
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Aug 13, 2019
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
May 28, 2019
Roche launches first in vitro diagnostic IHC test to detect ROS1 protein in cancers
May 15, 2019
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio
Dec 17, 2018
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
Nov 28, 2018
U.S./Australian Study Highlights Rapid Analysis and Clinical Utility of Liquid Biopsy Assay
Oct 19, 2018
Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting
Oct 17, 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Sep 27, 2018
IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer
Sep 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
Aug 29, 2018
The Bonnie J. Addario Lung Cancer Foundation Joins Forces with Patient Advocate Group to Advance Care for People with EGFR-Positive Lung Cancer
Jun 22, 2018
ALK and ROS1 Clones from CST Featured in Latest Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer
May 01, 2018
Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer
Apr 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
Apr 15, 2018
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
Feb 21, 2018
Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine